Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations

Infection, Supplement

Volumn 33, Issue 2, 2005, Pages 15-21

  Schubert, S ^a   Dalhoff, A ^a   Stass, H ^b   Ullmann, U ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CHLAMYDIA; COMPARTMENT MODEL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; DRUG PENETRATION; KLEBSIELLA PNEUMONIAE; LUNG ALVEOLUS MACROPHAGE; LUNG FLUID; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA; NONHUMAN; PHARMACODYNAMICS; RESPIRATORY TRACT MUCOSA; SIMULATION; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; EPITHELIUM; IN VITRO STUDY; INOCULATION; LUNG; PARAMETER; SERUM; TISSUE LEVEL;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; HUMANS; KLEBSIELLA PNEUMONIAE; LUNG; MODELS, BIOLOGICAL; OFLOXACIN; QUINOLINES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 31444434609     PISSN: 01732129     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-8203-1     Document Type: Conference Paper

References (72)

1. Donowitz GR, Mandell GL: Acute pneumonia. In: Mandell GL, Bennett JE, Dolin R (eds): Principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, London, Toronto, 5th edn, 2000, pp 717-743.
2. Riquelme R, Torres A, El-Ebiary M: Community acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 156: 1450-1455.
3. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H: Infective exacerbations of chronic bronchitis. Chest 1998; 113: 1542-1548.
4. Felmingham D, Washington J: Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens-findings of the Alexander Project 1992-1996. J Chemother 1999; 11 (Suppl. 1): 5-21.
5. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN: Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl. 2): 81-93.
6. Jones ME, Karlowsky JA, Blosser-Middleton R, Critchley IA, Karginova E, Thornsberry C, Sahm DF: Longitudinal assessment of antipneumococcal susceptibility in the United States. Antimicrob Agents Chemother 2002; 46: 2651-2655.
7. Reinert RR, Al-Lahham A, Lemperle M, Tenholte C, Briefs C, Haupts S, Gerards H.H, Lüttiken R: Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002; 49: 61-68.
8. Canton R, Loza E, Morosini I, Baquero F: Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J Antimicrob Chemother 2002; 50 (Suppl. 1): 9-24.
9. Jones RN: Resistance patterns among nosocomial pathogens. Trends over the past few years. Chest 2001; 119 (Suppl.): 3975-4045.
10. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Bradley JS: Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine and skin and soft tissue infections in pediatric patients. Eur J Clin Microbiol Infect Dis 2004; 23: 445-455.
11. Morrissey I, Robbins M, Viljoen L, Brown DFJ: Antimicrobial susceptibility of community-acquired respiratory tract pathogens of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by the BSAC methods. J Antimicrob Chemother 2005; 55: 200-208.
12. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embile J, Smith H, Hoban DJ: A critical review of the fluoroquinolones. Drugs 2002; 62: 13-59.
13. Wise R, Honeybourne D: Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999; 14: 221-229.
14. Talbot UM, Paton W, Paton JC: Uptake of Streptococcus pneumoniae by respiratory epithelial cells. Infect Immun 1996; 64: 3772-3777.
15. Craven N, Anderson JC: The location of Stophylococcus aureus in experimental chronic mastitis in the mouse and the effect on the action of sodium cloxacillin. Br J Exp Pathol 1979; 60: 453-459.
16. Anderson GG, Dodson KW, Hooton TM, Halogen SJ: Intracellular bacterial communities of uropathogenic Escherichia coli in urinary tract pathogenesis. Trends Microbiol 2004; 12: 424-430.
17. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ: Intracellular bacterial biofilm-like pools in urinary tract infection. Science 2003; 301: 105-107.
18. Kerrn MB, Struve C, Blom J, Frimodt-Moeller N, Krogfelt KA: Intracellular persistance of Escherichia coli in urinary bladders from mecillinam-treated mice. J Antimicrob Chemother 2005; 55: 383-386.
19. Hamill RJ, Vann JM, Proctor RA: Phagocytosis of Staphylococcus aureus by cultured bovine aortic endothelial cells: model of post adherence events endovascular infections. Infect Immun 1986; 54: 833-836.
20. von Eiff C, Backer K, Methe D, Lubritz G, Hockmann J, Schwarz T, Peters G: Intracellular persistance of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with Darier's disease. Clin Infect Dis 2001; 32: 1643-1647.
21. Lowy FD: Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol 2000; 8: 341-343.
22. Bronillette E, Grondin G, Shkreta L, Lacasse P, Talbot B: In vivo and in vitro demonstration that Staphylococcus aureus is an intracellular pathogen in the presence or absence of fibronectin binding proteins. Microb Pathog 2003; 35: 159-168.
23. Wiebel ER: The ultrastructure of the alveolar-capillary barrier. In: Fishman AP, Hecht WW (eds): The pulmonary circulation and interstitial space. The University of Chicago Press, Chicago 1969, PP 67-83.
24. Staehlin LA: Structure and function of intracellular junctions. Int Rev Cytol 1974; 39: 283-287.
25. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R: Concentration of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44: 835-838.
26. Andrews JM, Honeybourne D, Jevons G, Brenwald NP, Cumingham B, Wise R: Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 40: 573-577.
27. Fish DN, Chow AT: The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101-119.
28. Wise R: A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest 1999; 17: 365-387.
29. Grasso S, Meinardi G, de Carneri I, Tamassia V: New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Chemother 1978; 13: 570-576.
30. Stass H, Dalhoff A: Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high performance liquid chromategraphy with fluorescence detection using on-column focusing. J Chromatography 1997; B702: 163-174.
31. Dalhoff A: Pharmacodynamics of quinolones. Drugs 1995; 49 (Suppl. 2): 197-199.
32. Gibaldi M, Perrier D: Pharmacokinetics. 2nd edn, Marcel Dekker, New York.
33. Craig WA, Ebert SC: Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; (Suppl. 74): 63-70.
34. Dalhoff A, Ullmann U: Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur J Clin Microbiol Infect Dis 1990; 9: 479-487.
35. Vogelmann B, Craig WA: Kinetics of antimicrobial activity. J Pediatrics 1986; 108: 835-840.
36. Vogelmann B, Gudmundsson S, Legget J, Turnidge J, Eberts S, Craig WA: Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
37. Gerber AU: Impact of the antibiotic dosage schedule on efficacy in experimental soft tissue infections. Scand J Infect Dis 1990; (Suppl. 74): 147-154.
38. Drusano GL, Craig WA: Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 (Suppl. 3): 38-44.
39. Dawson SJ, Reeves DS: Therapeutic monitoring, the concentration-effect relationship and impact on the clinical efficacy of antibiotic agents. J Chemother 1997; 9 (Suppl. 1): 84-92.
40. Craig WA: Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 636-642.
41. Leggett JE, Ebert S, Fantin B, Craig WA: Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1990; (Suppl. 74): 179-184.
42. Rotschafter JC, Zabinski RA, Walker KJ: Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy 1992; 12: 64S-70S.
43. Dalhoff A: Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 1999; 43 (Suppl. B): 51-59.
44. Stahlmann R, Lode H: Concentration-effect relationship of the fluoroquinolones. In: Kuhlmann J, Dalhoff A, Zeiler HJ (eds): Quinolone antibacterials. American Society for Microbiology, Washington DC 1998; 407-420.
45. Schentag JJ, Nix DE, Forrest A: Pharmacodynamics of the fluoroquinolones. In: Hooper DC, Wolfson JS (eds): Quinolone antimicrobial agents, 2nd edn. American Society for Microbiology, Washington DC 1993; 259-271.
46. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
47. Schentag JJ: The relationship between ciprofloxacin blood concentrations, MIC values, bacterial eradication, and clinical outcome in patients with nosocomial pneumoniae. In: Gerrard C (ed): Ciprofloxacin IV. Defining its role in serious infections. Springer Verlag, Berlin 1994, pp 49-57.
48. Roosendaal R, Bakker-Woudenberg IA, van den Berghe J, van Raffe M, Vink van den Berg JC, Michel MF: Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and experimental pneumonia in leukopenic rats. Antimicrob Agents Chemother 1987; 31: 1809-1815.
49. Gould IM, Milne K, Jason C: Concentration-dependent bacterial killing, adaptive resistance and post-antibiotic effect of ciprofloxacin alone and in combination with gentamicin. Drugs under Experimental Clinical Research 1990; 16: 621-628.
50. Craig W: Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microbiol Infect Dis 1993; 12 (Suppl. 1): S6-8.
51. Chalkey LJ, Koornhof HJ: Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother 1985; 28: 331-342.
52. Dalhoff A, Peterson U, Endermann R: In vitro activity of BAY 12-8039, a new 8-methoxy quinolone. Chemotherapy 1996; 42: 410-425.
53. Dalhoff A: Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae. Drugs 1995; 49 (Suppl. 2): 194-196.
54. Hyatt JM, Nix DE, Stratton CW, Schentag JJ: In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 1711-1716.
55. Rustige C, Wiedemann B: Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model. Antimicrob Agents Chemother 1990; 34: 1107-1111.
56. Boswell FJ, Andrew JM, Wise R, Dalhoff A: Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999; 43 (Suppl. B): 43-49.
57. Kang SL, Rybak MJ, McGrath BJ, Kaatz GW, Seo SM: Pharmacodynamics of levofloxacin, ofloxacin and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994; 38: 2702-2709.
58. Odenholt I, Löwdin E, Cars O: Bactericidal effects of levofloxacin in comparison with those of ciprofloxacin and sparfloxacin. Clin Microbiol Infect 1998; 4: 264-270.
59. Visalli MA, Jacobs MR, Appelbaum PC: MIC and time-kill study of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicilin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996; 40: 362-366.
60. Wright DH, Hovde LB, Peterson ML, Hoang AD, Rotschafer JC: In vitro evaluation of pharmacodynamic outcome parameters for fluoroquinolones against Streptococcus pneumoniae. 6th Int Symp New Quin and Related Antibiotics, Denver, Colorado, USA, 1998; abstr. S15-13.
61. Florea NR, Tessier PR, Zhang C, Nightingale CH, Nicolau DP: Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother 2004; 48: 1215-1221.
62. MacGowan AP, Bowker K, Wootton M, Holt HA: The in vitro activity of moxifloacin against Haemophilus influenzae and Moraxella catarrhalis using a pharmacodynamic model. Clin Microbiol Infect 1999; 5: 195-200.
63. Klugman KP, Capper T: Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin. J Antimicrob Chemother 1997; 40: 792-802.
64. Boswell FJ, Andrews JM, Wise R: Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and post-antibiotic effect. Antimicrob Agents Chemother 1997; 41: 1377-1379.
65. Boswell FJ, Andrews JM, Wise R, Dalhoff A: Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999; 43 (Suppl. B): 43-49.
66. MacGowan AP, Rogers CA, Holt HA, Bowker KE: Activities of moxifloxacin against and emergence of resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003; 47: 1088-1095.
67. Odenholt I, Löwdin E, Gustafsson I, Cars O: Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model. Antimicrob Agents Chemother 2002; 46: 2046-2048.
68. Lister PD, Sanders CC: Pharmacodynamics of trovafloxacin, ofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1999; 43: 1118-1123.
69. Madaras-Kelly KJ, Ostergaard BE, Baeker-Horde L, Rotschafer JC: Twenty-four hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40: 627-632.
70. Odenholt I, Cars O, Löwdin E: Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against gram-positive and gram-negative bacteria. J Antimicrob Chemother 2000; 46: 35-43.
71. Wiedemann B, Rustige-Wiedemann C, Kratz B: Comparison of the pharmacodynamic properties of quinolones. Drugs 1995; 49 (Suppl. 2): 269-271.
72. Dalhoff A, Schmitz FJ: In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003; 22: 203-221.